How can CMS help ease the transition to value-based care?

The fee-for-service design of the healthcare industry has been the standard for the last 50-75 years. The simple fact remains that many stakeholders are still heavily invested in prolonging its tenure, even as irreversible steps are taken to ensure its eventual demise. As we make the inevitable transition to value-based care, certain questions still need… read more

DETERMINING THE PRICE OF POTENTIALLY LIFE SAVING ORAL THERAPY MEDICATIONS

The FDA has programs in place to focus on the development and designations for new specialty drugs. The problem is that high prices are being paid for drugs that don’t come with a graded, tested and proven high outcomes guarantee. The Institute for Clinical and Economic Review (ICER) evaluates evidence on the value of medical… read more

How do you weigh cost versus cure in hepatitis C treatment with high cost drugs?

When discussing high cost drugs proven to cure a specific illness, such as hepatitis C treatment, it’s important to keep the following in mind: All stakeholders – manufacturers, pharmacy benefit managers, pharmacies, payers and business owners – want a say in determining the cost of certain drugs because they all assume a certain level of… read more

Four ingredients needed for effective value-based pharma contracts

Value-based contracts between pharmaceutical manufacturers and payers are a fast-growing, new development that is here to stay. These pharma contracts put in place a reward system – higher payment rates – in exchange for demonstrably improved patient outcomes. This type of agreement is intended to reward healthcare value over volume. Some outcomes can be measured… read more

Cancer: what is the outlook for the newest chronic illness?

As medical cures advance, the umbrella covering chronic conditions does, too. Increasingly, the future of cancer treatment, with increased numbers of immunotherapies and oral oncolytics, will begin to emulate treatments for chronic illnesses. Along with this progress come big questions, like when, if ever will it be safe for a cancer patient to stop treatment?… read more

Learnings from the 2016 Asembia Specialty Pharmacy Summit

This year the Asembia Specialty Pharmacy Summit, previously known as the Armada Specialty Pharmacy Summit, left us with some key learnings. Here are four of my takeaways from Armada, nay, Asembia 2016: The absence of the PBMs was noticeable and curious. There were two PBMs with noticeably sparse attendance at this year’s gathering – Express… read more

Media contact: Kristin Lindsey, Marketing Director at 866-437-8040, extension 253 or klindsey@curanthealth.com

 
EmailEmailEmailEmail
Menu Title